AR
Arvinas
ARVN·NASDAQNew Haven CTFounded 2013450 employees
Mid CapbiotechPublicOncologyNeurology
Platform: PROTAC
Market Cap
$2.5B
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (ARVN)
Loading ARVN stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Zenonaritide | ARV-6632 | Phase 1/2 | 2 | BCL-2 | ALL | ||
| Tixatapinarof | ARV-4994 | Phase 1/2 | 1 | CDK2 | CSU | ||
| Lisonesiran | ARV-5389 | Phase 1/2 | 2 | PARP | MyelofibrosisTTR Amyloidosis |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (4)